Nutrition and Cancer-An International Journal最新文献

{"title":"Ultrasound Measurements of Skeletal Muscle Predict Chemotherapy Toxicity in Non-Small Cell Lung Cancer.","authors":"Huan Teng, Xiaolan Sun, Cheng Jiang, Aiping Liu, Xiaoqing Liu, Yanrong Chen, Weiting Jiang, Kun Zhang, Bo Liao","doi":"10.1080/01635581.2025.2512611","DOIUrl":"https://doi.org/10.1080/01635581.2025.2512611","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) patients often experience skeletal muscle mass (SMM) reduction, increasing chemotherapy toxicity risk. Although CT and MRI scans are commonly used to assess SMM, their limitations exist. Ultrasound, a convenient alternative, may serve as a predictive tool for chemotherapy toxicity.</p><p><strong>Methods: </strong>This multi-center, prospective study analyzed 163 NSCLC patients undergoing platinum-based chemotherapy. Ultrasound measured quadriceps muscle thickness (X-axis, Y-axis), cross-sectional area (CSA), fascicle length (FL), and pennation angle (PA). Chemotherapy toxicity was evaluated using CTCAE 5.0 criteria. Relationships between ultrasound parameters and toxicity were assessed <i>via</i> point-biserial correlation, logistic regression, and receiver operating characteristic curves (ROC) curve analyses.</p><p><strong>Results: </strong>Muscle thickness (X-axis, Y-axis), CSA, and PA were significantly correlated with overall toxicity and grade 3-4 hematologic toxicity (<i>p</i> < 0.05), with weaker correlations for non-hematologic toxicity. Multivariable logistic regression confirmed these parameters as independent predictors. ROC curve analysis revealed strong predictive value for CSA (AUC 0.796, cutoff 3.122 cm²) and X-axis thickness (AUC 0.768, cutoff 1.131 cm) in predicting grade 3-4 overall toxicity.</p><p><strong>Conclusion: </strong>Ultrasound measurements of quadriceps muscle effectively predict severe chemotherapy toxicity (grade 3-4), offering a non-radiative, accessible tool to identify high-risk NSCLC patients, enabling tailored interventions and improved treatment tolerance.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Comment on \"Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy\".","authors":"Kadriye Başkurt, Berkan Karabuğa, Nurlan Mammadzada, Osman Sütcüoğlu, Sercan Aksoy","doi":"10.1080/01635581.2025.2514277","DOIUrl":"https://doi.org/10.1080/01635581.2025.2514277","url":null,"abstract":"<p><p>We read with great interest the recent randomized controlled trial reporting that vitamin D supplementation significantly improves pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NCT). While the findings are noteworthy and contribute to the expanding literature on the supportive role of vitamin D in oncology, several critical methodological issues warrant further discussion. Specifically, the study did not adjust for key clinicopathologic variables-such as tumor subtype, T and N stage, lymphovascular invasion, and treatment intensity-that are well-established predictors of pCR. The lack of multivariate analysis raises concerns regarding potential confounding. Furthermore, the categorization of molecular subtypes lacked granularity, particularly in the distinction between luminal A and B tumors, which are known to exhibit divergent treatment responses. The study's narrow focus on pCR, without reporting other relevant pathological endpoints such as ypT/ypN stage or Miller-Payne grading, also limits its clinical interpretability. Importantly, ethical concerns arise from assigning patients with vitamin D deficiency to placebo, given the growing evidence supporting its correction in oncologic care. Addressing these limitations in future studies could enhance the reliability and translational relevance of the observed findings.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-2"},"PeriodicalIF":2.0,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Evaluation of Artificial Intelligence Models for Nutritional Symptom Management in Breast Cancer Patients Undergoing Chemotherapy\".","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"10.1080/01635581.2025.2514883","DOIUrl":"https://doi.org/10.1080/01635581.2025.2514883","url":null,"abstract":"","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-2"},"PeriodicalIF":2.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of 24-Hour Recalls to Assess Adherence to Cancer Specific Dietary Guidelines: Experiences from the Advancing Survivorship Cancer Outcomes Trial (ASCOT).","authors":"Victoria Ireland, Helen Croker, Sara Esser, Phillippa Lally, Rebecca J Beeken, Abigail Fisher, Rana Conway","doi":"10.1080/01635581.2025.2514783","DOIUrl":"10.1080/01635581.2025.2514783","url":null,"abstract":"<p><p>People living with and beyond cancer (LWBC) are advised to follow World Cancer Research Fund (WCRF) dietary guidelines. However, there is no established methodology to assess adherence. This study aimed to: (i) develop methodology to process dietary recalls into a format comparable to WCRF guidelines and (ii) evaluate the impact of additional data processing on estimates of dietary intake, in people LWBC. Advancing Survivorship Cancer Outcomes Trial (ASCOT) participants completed two 24-h dietary recalls at four timepoints using myfood24. Five WCRF recommendations (limiting consumption of energy dense foods, red meat and processed meat, and increasing consumption of fruit and vegetables and wholegrains and pulses) were operationalized (e.g. ≤ 500 g red meat per week). Quality control checks indicated the need for additional processing, including changing portion sizes and choosing alternative items from myfood24 to improve accuracy. Compared to myfood24 output, the processed dietary data indicated lower intake of fruit and vegetables, and higher intake of NSP and AOAC fiber (all ps < 0.001). Developing methodology to allow assessment of 24-h dietary recall data against WCRF guidelines was possible and necessary but resource intensive. Additional data processing impacted estimates of the key foods and nutrients consumed by trial participants in a meaningful way.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Obesity on Cancer-Specific Survival and Overall Survival in Colorectal Cancer.","authors":"Elvis Obomanu, Tinsae Anebo, Karecia Byfield, Abidemi Akinrinmade, Gabor Varadi","doi":"10.1080/01635581.2025.2514782","DOIUrl":"https://doi.org/10.1080/01635581.2025.2514782","url":null,"abstract":"<p><p>Obesity is a well-established risk factor for colorectal cancer (CRC) development, yet its influence on cancer-specific survival (CSS) and overall survival (OS) remains paradoxical. While obesity correlates with adverse outcomes such as increased recurrence, metastasis, and treatment-related complications, emerging evidence highlights a counterintuitive \"obesity paradox,\" where overweight and moderately obese patients with Body Mass Index(BMI 25-30) exhibit improved CSS and OS compared to underweight (BMI <18.5) or morbidly obese (BMI >35) individuals. Proposed mechanisms for this paradox include altered molecular signaling (adipokine imbalances), enhanced energy metabolism, and greater treatment tolerance due to metabolic reserves. However, these findings are contentious, as BMI, a crude measure, fails to distinguish lean mass from visceral adiposity, key determinants of prognosis. Studies suggest that moderate obesity may buffer treatment toxicity, while extremes of BMI reflect frailty or metabolic dysfunction, worsening survival. This review critically examines the biological underpinnings of the obesity paradox and challenges BMI's reliability as a prognostic tool. Research must prioritize advanced body composition metrics (visceral fat quantification <i>via</i> imaging) to disentangle obesity's dual role in CRC outcomes. Such precision could guide tailored interventions, transforming the paradox from a scientific curiosity into a therapeutic strategy, optimizing survival for CRC patients across the weight spectrum.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Nutritional Status by GLIM Criteria in Outpatients with GIST.","authors":"Yanglu Ou, Pan Ran, Qijuan Zhang, Jun Zhang, Juan Li","doi":"10.1080/01635581.2025.2512621","DOIUrl":"https://doi.org/10.1080/01635581.2025.2512621","url":null,"abstract":"<p><p>Nutritional management has proven to be significant in the treatment of cancer. Nonetheless, studies have rarely conducted on outpatients with gastrointestinal stromal tumor (GIST) currently. Data of outpatients with GIST at our hospital from June 1, 2020, to August 1, 2022, were retrospectively analyzed. The Malnutrition Universal Screening Tool was used to screen outpatients with GIST for malnutrition risk, and malnutrition was identified using the Global Leadership Initiative on Malnutrition (GLIM) criteria. We hypothesized that malnutrition is associated with poor clinical outcomes in patients with GIST. This study included a total of 173 outpatients with GIST (82 males [47.4%] and 91 females [52.6%]; average age: 58.96 ± 10.53 years). Nutritional risk distribution was low in 60.12% (<i>n</i> = 104) of patients, moderate in 21.39% (<i>n</i> = 37), and high in 18.50% (<i>n</i> = 32). Malnutrition was diagnosed in 27.75% (<i>n</i> = 48) of patients. Multivariate analysis revealed that reduced food intake and low hemoglobin level were significant factors associated with malnutrition. Importantly, GLIM-defined malnutrition significantly affected progression-free survival (PFS) (hazard ratio [HR]: 3.702, 95% confidence interval (CI): 1.384-9.902, <i>p</i> = 0.005). Outpatients with GIST exhibit a high risk of malnutrition, and nutritional management may improve their prognosis. The GLIM criteria are effective for assessing malnutrition and predicting clinical outcomes in outpatients with GIST.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Response to Comment on \"Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy\".","authors":"Michelle Sako Omodei, Jackeline Chimicoviaki, Daniel Araujo Brito Buttros, Benedito Souza Almeida-Filho, Carla Priscila Carvalho-Pessoa, Eduardo Carvalho-Pessoa, Heloisa De Luca Vespoli, Eliana Aguiar Petri Nahas","doi":"10.1080/01635581.2025.2513678","DOIUrl":"https://doi.org/10.1080/01635581.2025.2513678","url":null,"abstract":"","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-3"},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eight-Year Trends in Megestrol Acetate Prescription Among Korean Patients with Biliary-Pancreatic Cancer and Their Impact.","authors":"Hoonji Oh, Ju Won Kim","doi":"10.1080/01635581.2025.2508536","DOIUrl":"https://doi.org/10.1080/01635581.2025.2508536","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced anorexia and cachexia are significant challenges for patients with biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC). Megestrol acetate (MA), used to manage anorexia, has side effects and may trigger prescription cascades in cancer treatment. This study analyzed MA prescription trends and associated effects in BTC or PDAC patients.</p><p><strong>Methods: </strong>MA prescription rates among BTC or PDAC patients were examined using data from the Health Insurance and Review Assessment Service database in Korea. We investigated thrombosis and anti-coagulant prescription rates during the same period.</p><p><strong>Results: </strong>Analysis of 31,114 patients diagnosed with BTC or PDAC between 2009 and 2016 revealed significant increases in MA prescriptions: from 4.42% to 44.62% in BTC patients and from 7.56% to 63.15% in PDAC patients (<i>p</i> < 0.0001). In 2009, thrombosis was diagnosed in 5.58% of BTC patients and 6.83% of PDAC patients, rising to 7.62% and 12.47% by 2016. Anticoagulant prescriptions also increased, from 0.84% to 16.97% for BTC patients and from 2.37% to 15.96% for PDAC patients.</p><p><strong>Conclusion: </strong>MA prescriptions for BTC or PDAC patients increased significantly over 8 years. Patients on long-term MA had higher anticoagulant prescription rates compared to those not on long-term MA.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-7"},"PeriodicalIF":2.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional Evidence Chain of Nutritional Impact on Digestive System Tumors: Integration of Mendelian Randomization Causal Inference, NHANES Epidemiological Data, and Transcriptomic Analysis.","authors":"Yuan Chen, Yaodong Ping, Hong Liu, Benben Zhu, Xueyan Jiang, Rong Fu, Yiwei Hao, Yan Yang, Chunlei Miao, Yuli Liu","doi":"10.1080/01635581.2025.2508532","DOIUrl":"https://doi.org/10.1080/01635581.2025.2508532","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The global burden of digestive system tumors (e.g., hepatocellular carcinoma, gastric cancer, colorectal cancer) continues to rise, with low survival rates in advanced stages, necessitating etiology-based intervention strategies. Nutritional metabolic disorders are closely linked to tumor progression, but existing studies predominantly focus on correlational analyses, leaving causal relationships and molecular mechanisms poorly understood.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Integrating Mendelian randomization (MR), National Health and Nutrition Examination Survey (NHANES) epidemiological data, and transcriptomic data analysis, this study aims to elucidate the impact of nutritional status on digestive system tumors, identify key genes, develop prognostic models for precise nutritional interventions, and propose potential therapeutic directions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Causal Inference: MR analysis using OpenGWAS data to assess causal associations between nutritional symptoms and digestive system tumor. Epidemiological Validation: Restricted cubic spline models analyzed nonlinear associations between nutritional status (Geriatric Nutritional Risk Index [GNRI]) and telomere length (DNAmTL) in NHANES 1999-2002 data (&lt;i&gt;n&lt;/i&gt; = 2,532). Gender stratification and mediation effects tested nutritional pathways. Molecular Mechanism: Transcriptomic data from TCGA (CHOL, LIHC, COAD, etc.) identified malnutrition-related genes. Survival analysis, immune subtype classification (C1-C6), and tumor microenvironment scoring (ESTIMATE/RNAss) were integrated to build a Cox prognostic model. Machine learning (ML; Random Forest/Support Vector Machine) screened key genes. CellMiner database linked gene expression to drug sensitivity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Causal Association: MR confirmed significant causal effects of nutrition on digestive system tumor risk (&lt;i&gt;P&lt;/i&gt;&lt;sub&gt;IVW&lt;/sub&gt; &lt; 0.05). Gender Heterogeneity: Males exhibited accelerated telomere shortening at GNRI &gt; 115 (&lt;i&gt;β&lt;/i&gt; = -0.0123/unit, &lt;i&gt;P&lt;/i&gt; = 0.035), while females showed no significant association. Dietary quality (Healthy Eating Index) directly protected telomeres (&lt;i&gt;β&lt;/i&gt; = 0.069, &lt;i&gt;P&lt;/i&gt; = 0.003), linked to seafood/plant protein (&lt;i&gt;β&lt;/i&gt; = 0.066) and whole fruit intake (&lt;i&gt;β&lt;/i&gt; = 0.067). Key Genes: ML identified ACTG2, MSX1, and COL7A1 as core drivers. Prognostic Model: A risk score model (ATP6V0A1*0.70 + TP63*0.37 + SLC7A7*0.49 + ARHGAP29*0.33 + CDH1*(-0.50)) distinguished high/low-risk groups (AUC = 0.977). Potentially Available Drugs: Zoledronate, LY-294002, and Everolimus may be potential choices for malnutrition digestive tract tumors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This study systematically reveals multidimensional mechanisms linking malnutrition to digestive system tumor progression &lt;i&gt;via&lt;/i&gt; genetic, molecular, and immune pathways. Key genes (ACTG2, MSX1, COL7A1) and gender-specific interventions offer novel strategies for precision on","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-18"},"PeriodicalIF":2.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Height and Body Mass Index Changes in Chinese Children Undergoing Chemotherapy for Acute Lymphoblastic Leukemia.","authors":"Yixiao Chen, Jing Miao, Xinyi Liang, Jingying Zhang, Weiqun Xu, Hua Song, Yongmin Tang, Junfen Fu, Xiaojun Xu","doi":"10.1080/01635581.2025.2505261","DOIUrl":"https://doi.org/10.1080/01635581.2025.2505261","url":null,"abstract":"<p><strong>Background: </strong>Children with acute lymphoblastic leukemia (ALL) have a higher risk of height deficit and obesity. Data on Chinese pediatric ALL patients treated on chemotherapy only are limited.</p><p><strong>Methods: </strong>Changes in z scores for height and body mass index (BMI) from the diagnosis to 2 years after the initial of treatment were analyzed in 805 ALL patients diagnosed at Children's Hospital of Zhejiang University School of Medicine.</p><p><strong>Results: </strong>A significant reduction in height z-scores and increase in BMI z-scores were documented during treatment (<i>p</i> < 0.001), the most pronounced changes observed in the first three months. Catch-up growth was noted after nine months. Children in middle-high-aged group showed the most significant decline in height z-scores after 24 months (<i>p</i> < 0.05). High-risk patients exhibited lower height z-scores at 9 and 12 months (<i>p</i> < 0.01). Children under 9 years or in non-high-risk group showed greater BMI z-scores increase during treatment (<i>p</i> < 0.05). There were no significant differences by gender.</p><p><strong>Conclusion: </strong>Chemotherapy leads to height deficit and BMI increase in pediatric ALL patients. Height deficit is more pronounced in children aged 8-13 years, BMI increases are more significant in younger children. High-risk patients are more prone to lower height and smaller BMI increases.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}